ACAAI 2023 Annual Scientific Meeting Recap: Day 1

Treatment Advances, Insights Expected at the 2023 ACAAI Annual Scientific Meeting

New treatments and clinical insights will be shared at this year's American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

Remibrutinib Improves Chronic Spontaneous Urticaria Symptoms at Week 2

New findings are shared from the phase 3 REMIX-1 (NCT05030311) and REMIX-2 trials (NCT05032157) evaluating remibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of chronic spontaneous urticaria (CSU).

Addressing Mental Health Issues in Patients With Atopic Dermatitis

Are you addressing your patients' mental health? A new study emphasizes the importance of talking to your patients and helping them find support.

Jay A. Lieberman, MD, FACAAI: Clinical Pearls and Hands-On Educational Opportunities at ACAAI Annual Meeting

Program Chair Jay A. Lieberman, MD, FACAAI, shares exciting programs at this year's meeting.


Ruchi Gupta, MD, MPH: Challenges and Opportunities in Managing AD in College

Atopic dermatitis can be challenging for patients, especially for young adults heading off to college. These tips will help you better support your patients (and their families).

Are you attending this year's meeting? Share your thoughts and comments with us via social media or DTEditor@mmhgroup.com